pharma · Acute Myeloid Leukemia · Advanced Hematologic Malignancy · FHTX
Foghorn Therapeutics
Foghorn Therapeutics patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2016
- Employees
- 124
- Programs
- 5
- Drugs
- 2
- Patents
- 14
Foghorn Therapeutics patents
14 pharmaceutical patents indexed for Foghorn Therapeutics. 0 expire within 24 months.
Foghorn Therapeutics has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12391686
Compounds and uses thereof
granted -
US 12383555
Methods of treating cancers
granted -
US 12383560
Compounds and uses thereof
granted -
US 12384776
Compounds and uses thereof
granted -
US 12351579
Compounds and uses thereof
granted -
US 12139487
Compounds and uses thereof
granted -
US 11851445
Compounds and uses thereof
granted -
US 11787800
BRD9 degraders and uses thereof
granted -
US 11773085
Methods and compounds for treating disorders
granted -
US 11767330
Citrate salt, pharmaceutical compositions, and methods of making and using the same
granted -
US 11560381
Compounds and uses thereof
granted -
US 11497752
Compounds and uses thereof
granted -
US 11485732
Compounds and uses thereof
granted -
US 11414416
Compounds and uses thereof
granted
Frequently asked questions
How many patents does Foghorn Therapeutics have?
14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Foghorn Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.